MESOBLAST LTD
MESO, MEOBF · Biological Products, (No Diagnostic Substances) · EDGAR filings ↗
Reference price $1.48 — last insider purchase, 2026-04-10 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
D45gen composite 52pct→69; net margin <-100%; net + operating loss
Notable findings
- High convictionHigh conviction — notable institutional holders, insider buying, and a strong balance sheet
- Cash burnNegative free cash flow (-50.6M)
- Net lossNet loss (net margin -593.9%)
- Insider buyingInsider buying — 30 open-market buy(s) by 1 insider(s) (~$38M, last 6mo) Form 4 ↗
- Strong balance sheetStrong balance sheet — $162M cash & investments, ~13 quarters of runway
- Notable holderHeld by 2 notable fund(s): CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
70.2%
Net margin
-593.9%
Return on equity
-17.1%
Return on assets
-13.0%
Revenue growth (QoQ)
191.4%
Debt / equity
0.2×
Current ratio
2.0×
Free cash flow
-$51M
Tangible book value
$597M
Cash & investments
$162M
Cash runway
13q
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| George Gregory | Director | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Insider transactions · last 6 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-10 | George Gregory | Buy | 2.3M | $1.48 |
| 2026-04-10 | George Gregory | Buy | 2.3M | $1.48 |
| 2026-04-09 | George Gregory | Buy | 500K | $1.44 |
| 2026-04-09 | George Gregory | Buy | 10K | $1.44 |
| 2026-04-09 | George Gregory | Buy | 4.8K | $1.44 |
| 2026-04-09 | George Gregory | Buy | 20K | $1.43 |
| 2026-04-09 | George Gregory | Buy | 10K | $1.43 |
| 2026-04-09 | George Gregory | Buy | 5.2K | $1.43 |
| 2026-04-09 | George Gregory | Buy | 10K | $1.43 |
| 2026-04-09 | George Gregory | Buy | 5.0K | $1.43 |
| 2026-04-09 | George Gregory | Buy | 10K | $1.43 |
| 2026-04-09 | George Gregory | Buy | 10K | $1.43 |
| 2026-04-09 | George Gregory | Buy | 10K | $1.41 |
| 2026-04-09 | George Gregory | Buy | 887K | $1.43 |
| 2026-04-09 | George Gregory | Buy | 887K | $1.43 |
| 2026-04-09 | George Gregory | Buy | 500K | $14.39 |
| 2026-04-09 | George Gregory | Buy | 500K | $14.39 |
| 2026-04-09 | George Gregory | Buy | 10K | $14.40 |
| 2026-04-09 | George Gregory | Buy | 4.8K | $14.40 |
| 2026-04-09 | George Gregory | Buy | 20K | $14.30 |
| 2026-04-09 | George Gregory | Buy | 10K | $14.30 |
| 2026-04-09 | George Gregory | Buy | 5.2K | $14.25 |
| 2026-04-09 | George Gregory | Buy | 10K | $14.25 |
| 2026-04-09 | George Gregory | Buy | 5.0K | $14.30 |
| 2026-04-09 | George Gregory | Buy | 10K | $14.30 |
| 2026-04-09 | George Gregory | Buy | 10K | $14.10 |
| 2026-04-09 | George Gregory | Buy | 10K | $14.30 |
| 2026-04-09 | George Gregory | Buy | 105K | $1.46 |
| 2026-04-04 | George Gregory | Buy | 4.0M | $1.42 |
| 2026-04-04 | George Gregory | Buy | 4.0M | $1.42 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06325566 ↗ | Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain Degenerative Disc Disease | PHASE3 | Active Not Recruiting | 2027-07-01 |
| NCT07568535 ↗ | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease GVHD - Graft-Versus-Host Disease | PHASE3 | Not Yet Recruiting | 2028-02-28 |
| NCT04548583 ↗ | Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis Crohn Colitis | PHASE1/PHASE2 | Terminated | 2023-11-15 |
| NCT04543994 ↗ | Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) Ulcerative Colitis | PHASE1/PHASE2 | Terminated | 2023-11-15 |
| NCT01781390 ↗ | Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction Acute Myocardial Infarction | PHASE2 | Completed | 2021-04-06 |
| NCT04371393 ↗ | MSCs in COVID-19 ARDS Mesenchymal Stromal Cells, Remestemcel-L | PHASE3 | Terminated | 2021-01-14 |
| NCT02412735 ↗ | Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain Degenerative Disc Disease | PHASE3 | Completed | 2020-05-15 |
| NCT02032004 ↗ | Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure Chronic Heart Failure | PHASE3 | Completed | 2020-01-30 |
| NCT02652130 ↗ | Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease | PHASE3 | Completed | 2018-06-15 |
| NCT02336230 ↗ | A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) Grade B aGVHD, Grade C aGVHD | PHASE3 | Completed | 2018-04-09 |
| NCT01854567 ↗ | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | PHASE3 | Completed | 2016-09-23 |
| NCT01851070 ↗ | A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor Rheumatoid Arthritis | PHASE2 | Completed | 2016-05-01 |
| NCT01233960 ↗ | Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease Crohn's Disease | PHASE3 | Completed | 2014-09-15 |
| NCT00482092 ↗ | Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease Crohn's Disease | PHASE3 | Completed | 2014-09-15 |
| NCT01843387 ↗ | Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy Diabetic Nephropathy, Type 2 Diabetes | PHASE1/PHASE2 | Completed | 2014-09-01 |
| NCT01088191 ↗ | Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction Anterior Cruciate Ligament Injury, Osteoarthritis | PHASE1/PHASE2 | Completed | 2013-11-01 |
| NCT01576328 ↗ | Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes Type 2 Diabetes | PHASE1/PHASE2 | Completed | 2013-10-01 |
| NCT00549913 ↗ | Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF) Degenerative Disc Disease, Spondylolisthesis | PHASE1/PHASE2 | Completed | 2013-08-01 |
| NCT01097486 ↗ | Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis | PHASE2 | Completed | 2013-07-01 |
| NCT01290367 ↗ | Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain Degenerative Disc Disease | PHASE2 | Completed | 2013-07-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-08-29 | 2025-06-30 | 0001345099-25-000067 ↗ |
| 20-F | 2024-08-29 | 2024-06-30 | 0001345099-24-000063 ↗ |
| 20-F | 2023-08-31 | 2023-06-30 | 0001345099-23-000059 ↗ |
| 20-F | 2022-08-31 | 2022-06-30 | 0001564590-22-030576 ↗ |
| 20-F | 2021-08-31 | 2021-06-30 | 0001564590-21-046486 ↗ |
| 20-F | 2020-09-03 | 2020-06-30 | 0001564590-20-042401 ↗ |
| 20-F | 2019-09-09 | 2019-06-30 | 0001564590-19-034304 ↗ |
| 20-F | 2018-08-31 | 2018-06-30 | 0001564590-18-022521 ↗ |
| 20-F | 2017-08-30 | 2017-06-30 | 0001564590-17-018168 ↗ |
| 20-F | 2016-08-25 | 2016-06-30 | 0001564590-16-024688 ↗ |